2m 2m 2m 2m 2m 2m 2m
ALAUNOS (TCRT)
NASDAQ
$1.52+$0.005 (+0.33%)
Price as of Sep 11, 2026 7:53 PM EDT- $3.8MMarket Cap
- -34.63%1-Year Change
- BiotechnologyIndustry
ALAUNOS (TCRT)
$1.52+$0.005 (+0.33%)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 55
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreDay Range
$1.50
$1.53
$1.51
1-Year Range
$1.51
$4.36
$1.51
Latest Close$1.51
Change
-$0.05 (-3.28%)
Volume18,275
Market Cap$3.8M
Shares Outstanding2.5M
P/E (TTM)-0.84
Diluted EPS (TTM)-$1.81
Enterprise Value$3.7M
Information as of 09/11/2026
Company Profile
ALAUNOS THERAPEUTICS INC
https://www.alaunos.com$3.8M
Market Cap
-$4.0M
Net Income
Sector: Healthcare
Industry: Biotechnology
501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301
346 355 4099Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Key Executives
- Holger Weis
- Ferdinand Groenewald
Current Ownership Distribution
- Institutions572.1M (77.46%)
- Mutual Funds161.5M (21.87%)
- Insiders5.0M (0.67%)
- Other0 (0.00%)